🔓
Sign in as a Member to unlock the full view of HR.9774. · Full carveout list, all affected companies, party defectors, and 30-day trade predictions.
Become a Member$24.50/mo already a Member? Sign in →
HR.9774 · 119TH CONGRESS

To amend the Federal Food, Drug, and Cosmetic Act to provide for expedited approval of priority nonprescription drugs, and for other purposes.

Status
In Committee
Latest Action
2026-07-20
Sponsor
Latta, Robert E. (R-Ohio)
Official Source
Congress.gov
Investability
0/100
Stage
COMMITTEE
Related Bills
0
Full Text
Unavailable
Alive
Yes

What This Bill Does · Plain English

Summary
Plain-English summary not yet available for this bill. Check back after our next analysis run.

Frequently Asked Questions

Did HR.9774 pass?
HR.9774 is still alive. Current stage: COMMITTEE. Pass likelihood: pending.
Who sponsored HR.9774?
HR.9774 was sponsored by Robert E. Latta (R-Ohio).

Full Bill Text

⚖️ View on Congress.gov 📄 PDF (GovInfo) 🔗 Copy link
Full text not yet indexed for this bill. Check Congress.gov for the official text.
🔒 GovGreed Pro · Trading Intelligence on HR.9774 Get Access — $24.50/mo
Loading intelligence layer…
Bill text sourced from GovInfo.gov · public domain · last updated 2026-07-29. Plain-English summary, score breakdown, and trading-intelligence panels are GovGreed-original analysis derived from STOCK Act filings, SEC Form 4 disclosures, FEC contributions, and Senate LDA lobbying reports — all publicly filed federal records. GovGreed is not affiliated with the U.S. Government. Not financial advice. [live render]